2021
DOI: 10.1016/j.ccc.2020.11.012
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers in Acute Kidney Injury

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
17
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 24 publications
(17 citation statements)
references
References 69 publications
0
17
0
Order By: Relevance
“…Many other biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (Kim-1), tissue inhibitor of metalloproteinase-2 (TIMP-2) × insulin-like growth factor-binding protein 7 (IGFBP7), and C–C Motif Chemokine Ligand 14 (CCL14) have been studied for diagnostic value in early AKI detection [ 4 ]. However, these biomarkers reflect the cell injury in the setting of AKI, other than the cell function, which can identify a patient’s predisposition and risk of developing AKI.…”
Section: Introductionmentioning
confidence: 99%
“…Many other biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (Kim-1), tissue inhibitor of metalloproteinase-2 (TIMP-2) × insulin-like growth factor-binding protein 7 (IGFBP7), and C–C Motif Chemokine Ligand 14 (CCL14) have been studied for diagnostic value in early AKI detection [ 4 ]. However, these biomarkers reflect the cell injury in the setting of AKI, other than the cell function, which can identify a patient’s predisposition and risk of developing AKI.…”
Section: Introductionmentioning
confidence: 99%
“…Their clinical application could possibly help in differentiating several phenotypes of AKI based on etiology, prognosis, and molecular pathways, which potentially may require different therapies [32]. Excellent reviews summarizing an impressive number of studies covering several aspects of the usefulness and limitations of these biomarkers are available for the interested reader [61][62][63][64][65][66]. Some biomarkers such as neutrophil gelatinaseassociated lipocalin (NGAL), and the cell-cycle biomarkers [metalloproteinase inhibitor 2] × [insulin-like growth factor-binding protein 7] ([TIMP-2] × [IGFBP7]), have been approved by regulatory authorities in some countries.…”
Section: Novel Biomarkers and Their Possible Impact On Definition And...mentioning
confidence: 99%
“…Therefore, discovering risk factors of AKI in patients with TBI in the early phase and evaluating the possibility of developing AKI among them are essential to avoid the occurrence of AKI by reducing the usage of nephrotoxic drugs and adjusting treatment strategies. Recently, some research studies explored the value of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and insulin-like growth factor-binding protein-7 (IGFBP-7) in evaluating the risk of AKI and even diagnosing AKI among critically ill patients, such as TBI (3)(4)(5)(6)(7)(8)(9)(10). However, the results of these studies showed different values of these markers in predicting AKI.…”
Section: Introductionmentioning
confidence: 99%